BridgeBio
BBIO
$76.75
-0.98%
BridgeBio Pharma is a biotechnology company focused on discovering, developing, and delivering transformative treatments for patients with genetic diseases, operating within the high-risk, high-reward biotechnology industry. The company has established itself as a platform-based biotech with a diversified pipeline, distinct for its focus on Mendelian disorders, oncology, and gene therapy, with its lead asset, acoramidis (Attruby), targeting transthyretin amyloid cardiomyopathy. The current investor narrative is overwhelmingly centered on the company's transition from a clinical-stage entity to a commercial-stage company, driven by the successful Phase 3 trial data for its achondroplasia treatment and the planned FDA filing in 2026, which has fueled significant optimism and driven the stock to near its 52-week highs.…
BBIO
BridgeBio
$76.75
Related headlines
Investment Opinion: Should I buy BBIO Today?
Rating: Hold. The core thesis is that BridgeBio's transformative commercial growth and pipeline potential are compelling, but these are fully priced into an extreme valuation, creating asymmetric risk/reward skewed to the downside in the near term.
Supporting this view are several data points: the trailing PS ratio of 30.05 is exceptionally high, indicating a premium for future growth; while revenue growth is strong at 25.21% YoY, it must accelerate dramatically to meet the $4.12 billion consensus estimate; the company remains deeply unprofitable with a -127.9% net margin; and free cash flow is deeply negative at -$457.60 million TTM. The stock's technical position near 52-week highs also suggests limited near-term upside without a new catalyst.
The thesis would upgrade to a Buy if the PS multiple compressed meaningfully (e.g., below 20x) on non-fundamental weakness, or if the company demonstrated a clear path to reducing cash burn ahead of schedule. It would downgrade to a Sell if quarterly revenue growth decelerated significantly below 20%, if the cash runway fell below 12 months without a clear funding plan, or if key clinical/regulatory catalysts failed. Relative to its own history and the high-growth biotech peer group, the stock is overvalued, trading at a premium that demands flawless execution.
Sign up to view all
BBIO 12-Month Price Forecast
The outlook is bifurcated between stellar execution and a painful derating. The base case, with a 50% probability, sees the stock trading sideways as it digests its massive gains and proves it can grow into its valuation. The key near-term monitor is the balance between revenue growth and cash consumption. The stance is neutral due to the high risk/reight ratio; the substantial upside in the bull case is offset by the severe downside in the bear case. We would upgrade to bullish on evidence of sustainable margin improvement or a successful non-dilutive financing, and downgrade to bearish on any material revenue shortfall or clinical setback.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BridgeBio's 12-month outlook, with a consensus price target around $99.78 and implied upside of +30.0% versus the current price.
Average Target
$99.78
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$61 - $100
Analyst target range
BridgeBio enjoys robust analyst coverage, with 15 analysts providing estimates, reflecting its status as a prominent mid-to-large-cap biotech story. The consensus sentiment is overwhelmingly bullish, as evidenced by the institutional ratings data showing a series of reiterated 'Outperform', 'Overweight', and 'Buy' ratings from major firms like JP Morgan, Morgan Stanley, and Wells Fargo throughout early 2026. The average analyst target price is not explicitly provided in the data, but the estimated EPS average of $8.82 and revenue average of $4.12 billion for the forward period indicate strong growth expectations. The target price range is implied by the estimated EPS range of $5.91 (low) to $10.83 (high); applying a reasonable forward PE multiple (given the forward PE of 372.57 is nonsensical for a profitable company and is likely a data error) would suggest a wide target range, signaling high uncertainty around the exact trajectory of profitability and market penetration. The high-end estimates likely assume successful FDA filings, rapid market adoption for acoramidis and the achondroplasia drug, and minimal competitive erosion, while the low-end estimates may factor in commercialization delays, pricing pressures, or clinical setbacks. The recent pattern of reiterated bullish ratings, without downgrades, suggests sustained institutional confidence in the company's near-term catalysts and long-term strategy.
Bulls vs Bears: BBIO Investment Factors
The bull case, supported by explosive revenue growth, strong analyst sentiment, and key near-term catalysts, currently holds stronger evidence, as reflected in the stock's 126% annual gain. However, the bear case presents substantial and concrete risks centered on extreme valuation, massive cash burn, and deep unprofitability. The single most important tension in the investment debate is between the market's pricing of flawless future execution (a $4.12B revenue forecast at a 30x PS multiple) and the company's present financial reality of significant losses and cash burn. The resolution of this tension—whether BridgeBio can grow into its valuation before exhausting its financial runway—will ultimately determine the stock's direction.
Bullish
- Explosive Revenue Growth & Commercialization: Revenue has surged from minimal levels to a meaningful $154.18 million in Q4 2025, representing 25.21% YoY growth. Sequential quarterly growth from $116.63M to $154.18M in 2025 demonstrates robust commercial execution for its lead assets, marking a critical inflection point from clinical to commercial stage.
- Strong Analyst Sentiment & High Growth Estimates: Analyst consensus projects massive forward revenue of $4.12 billion, implying a significant drop from the current trailing PS ratio of 30.05. With 15 analysts providing coverage and a pattern of reiterated 'Buy' and 'Outperform' ratings, institutional confidence in the company's near-term catalysts and long-term strategy remains high.
- Exceptional Gross Margin Profile: The company boasts a gross margin of 90.0% for Q4 2025, typical for a commercial-stage biotech with proprietary drugs. This indicates that once revenue is generated, it is highly profitable, providing a strong foundation for future profitability as sales scale.
- Powerful Technical Uptrend & Momentum: The stock has appreciated 126.60% over the past year and is trading near its 52-week high of $84.94. This powerful uptrend reflects sustained investor optimism and momentum, driven by successful Phase 3 trial data and the transition narrative.
Bearish
- Massive Cash Burn & Path to Profitability: The company reported a Q4 2025 net loss of $197.24 million and has a trailing twelve-month free cash flow of -$457.60 million. With $572.14 million in cash, the aggressive burn rate necessitates future capital raises or partnerships, creating dilution risk and questioning the timeline to self-sufficiency.
- Extremely High Valuation Multiples: A trailing PS ratio of 30.05 is extraordinarily high, even for a high-growth biotech, indicating the market has priced in near-perfect execution of its $4.12 billion revenue forecast. This leaves little room for multiple expansion and increases vulnerability to any growth disappointment.
- Deep Unprofitability & High Operating Losses: Operating losses remain substantial at -$185.24 million for Q4 2025, driven by high R&D ($142M) and SG&A ($182M) expenses. The net margin of -127.9% underscores that despite strong gross margins, the path to net profitability is long and capital-intensive.
- Technical Exhaustion & High Relative Valuation: Trading at 90% of its 52-week range near resistance at $84.94, the stock appears extended. Recent 3-month performance of +0.64% and 1-month relative strength of 2.10 vs. SPY's 7.36% suggest short-term exhaustion and potential for a consolidation or pullback.
BBIO Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by its staggering 126.60% price appreciation over the past year. With a current price of $76.75, it is trading at approximately 90% of its 52-week range ($31.77 to $84.94), positioning it near the upper bounds of its yearly high. This proximity to the 52-week high signals strong momentum but also suggests the stock is extended and may be vulnerable to a pullback or consolidation as it approaches a key technical resistance level. Recent momentum shows a deceleration from the longer-term trend, with a 9.46% gain over the past month but a more modest 0.64% gain over the past three months, indicating a period of consolidation following the explosive move higher. The 1-month relative strength of 2.10 versus the SPY's 7.36% gain shows the stock has recently underperformed the broader market on a relative basis, a potential sign of short-term exhaustion. Key technical support is anchored at the 52-week low of $31.77, while immediate resistance sits at the 52-week high of $84.94; a decisive breakout above $84.94 would signal a resumption of the primary uptrend, while a breakdown below the recent consolidation range around $65-$70 could indicate a deeper correction. With a beta of 1.09, the stock exhibits volatility roughly in line with the broader market, suggesting its dramatic moves are driven more by company-specific catalysts than systemic market risk.
Beta
1.09
1.09x market volatility
Max Drawdown
-20.3%
Largest decline past year
52-Week Range
$32-$85
Price range past year
Annual Return
+126.6%
Cumulative gain past year
| Period | BBIO Return | S&P 500 |
|---|---|---|
| 1m | +9.5% | +9.5% |
| 3m | +0.6% | +2.7% |
| 6m | +39.7% | +5.8% |
| 1y | +126.6% | +34.9% |
| ytd | -1.9% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BBIO Fundamental Analysis
BridgeBio's revenue trajectory has transformed dramatically, surging from minimal levels to a meaningful commercial scale, with Q4 2025 revenue of $154.18 million representing a 25.21% year-over-year growth. This growth is primarily driven by its 'Product' segment, which contributed $254.26 million over the trailing period, indicating successful commercialization of its lead assets, a critical inflection point for the company. The sequential trend from Q1 to Q4 2025 shows revenue accelerating from $116.63 million to $154.18 million, signaling robust commercial execution and demand for its therapies. The company remains deeply unprofitable on a net income basis, reporting a Q4 2025 net loss of $197.24 million, translating to a net margin of -127.9%. However, its gross margin is exceptionally strong at 90.0% for the quarter, which is typical for a commercial-stage biotech with proprietary drugs, indicating its revenue is high-margin once generated. The path to profitability is the central question, as operating losses remain substantial at -$185.24 million for the quarter, driven by high R&D ($142 million) and SG&A ($182 million) expenses necessary to fuel its pipeline and commercial efforts. Financially, the company maintains a solid liquidity position with a current ratio of 2.62 and $572.14 million in cash at the end of Q4 2025, but it is burning cash aggressively, with trailing twelve-month free cash flow of -$457.60 million. The negative debt-to-equity ratio of -1.31 is an accounting artifact due to an accumulated deficit, but the company's ability to continue funding its operations hinges on its cash balance and future capital raises or partnership deals, given the significant ongoing cash burn from operations and R&D.
Quarterly Revenue
$154180000.0B
2025-12
Revenue YoY Growth
+25.21%
YoY Comparison
Gross Margin
+0.90%
Latest Quarter
Free Cash Flow
$-457602000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BBIO Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. BridgeBio trades at a trailing PS ratio of 30.05, which is extraordinarily high by absolute standards but must be contextualized within the high-growth biotech sector. The forward-looking expectation is for massive revenue growth, with analyst consensus estimating revenue of $4.12 billion, which, at the current market cap, implies a forward PS multiple that is significantly lower, highlighting the market's pricing of exponential future sales growth. A direct peer comparison is challenging without provided industry averages, but the current PS multiple of 30x suggests the market is assigning a substantial premium for its commercial launch success and late-stage pipeline potential, typical for a biotech on the cusp of profitability. Historically, the stock's own PS ratio has compressed dramatically from levels above 800x in early 2024 to the current 30x, reflecting the transition from a pre-revenue to a commercial-stage entity. The current PS of 30.05 is at the lower end of its own recent historical range (from Q4 2024's 97.85), suggesting the market has already priced in a significant portion of the near-term commercial success, leaving less room for multiple expansion and placing greater emphasis on execution against the lofty revenue estimates.
PE
-20.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -38x~-2x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-25.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's unsustainable cash burn. With trailing FCF of -$457.60 million and a Q4 net loss of -$197.24 million, the $572.14 million cash balance provides a limited runway, likely necessitating dilutive equity raises or costly debt within 12-18 months. Furthermore, the path to profitability is obscured by high operating expenses (R&D and SG&A totaled $324M in Q4), and revenue, while growing, remains far from the scale needed to cover these costs, creating persistent earnings volatility.
Market & Competitive Risks are elevated due to the stock's extreme valuation. A PS ratio of 30.05, though down from historical highs, prices in near-perfect execution of massive growth. Any disappointment in revenue trajectory, competitive news in its core markets (e.g., transthyretin amyloid cardiomyopathy or achondroplasia), or a sector-wide derating of high-multiple biotech stocks could trigger significant multiple compression. The stock's beta of 1.09 suggests it is not immune to broader market downturns, which could exacerbate selling pressure on a richly valued name.
Worst-Case Scenario involves a combination of a clinical or regulatory setback for a key pipeline asset (e.g., FDA rejection or delay for the achondroplasia drug), coupled with slower-than-expected commercial adoption for acoramidis. This would lead to analyst downgrades, a collapse in the growth premium (PS compression towards 10-15x), and heightened concerns over the cash burn timeline, forcing a highly dilutive capital raise. This chain of events could realistically drive the stock back towards its 52-week low of $31.77, representing a downside of approximately -59% from the current price of $76.75.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company is burning cash aggressively (-$457.6M TTM) with a finite runway, risking highly dilutive financing. 2) Valuation & Execution Risk: The PS ratio of 30.05 prices in perfect growth; any revenue miss or delay could cause severe multiple compression. 3) Regulatory & Clinical Risk: The investment thesis depends on successful FDA filings and approvals for lead assets like the achondroplasia drug planned for 2026. 4) Competitive Risk: Other companies are developing treatments for TTR-CM and achondroplasia, which could erode market share and pricing power.
Our 12-month forecast outlines three scenarios. The Base Case (50% probability) sees the stock trading between $70 and $90 as the company executes in line with high expectations but struggles with multiple expansion. The Bull Case (25% probability) could drive the stock to $95-$115 on flawless execution and positive regulatory news. The Bear Case (25% probability) could see a collapse to $32-$55 on revenue misses, regulatory setbacks, or a forced capital raise. The most likely outcome is the Base Case, where the stock consolidates its massive gains while the company works to grow into its valuation.
Based on traditional metrics, BBIO is significantly overvalued. It trades at a trailing Price-to-Sales (PS) ratio of 30.05, which is extremely high by any absolute standard. This valuation implies the market expects flawless execution of massive future growth, with revenue needing to hit the $4.12 billion analyst consensus to bring the forward multiple down to a more reasonable level. Compared to its own history, the multiple has compressed from over 97x in late 2024, but it remains at a premium that leaves no room for error. The valuation is not supported by current profitability, with a net margin of -127.9%.
BBIO is a speculative buy only suitable for investors with a high risk tolerance. The stock offers significant potential upside if the company successfully executes its commercial launch and pipeline, with analyst consensus projecting revenue to surge to $4.12 billion. However, at a current PS ratio of 30.05, this optimism is fully priced in, and the downside risk is substantial, with a realistic bear case target near its 52-week low of $31.77 (-59% downside). It may be a good buy for aggressive growth investors on a meaningful pullback, but at current levels, the risk/reward is balanced, warranting a Hold stance.
BBIO is unsuitable for short-term trading due to its high volatility (beta 1.09), binary catalyst nature, and current extended technical position near 52-week highs. It is a long-term, speculative growth investment for investors willing to hold through potential significant drawdowns over a 3-5 year period to realize its pipeline potential. The lack of a dividend and focus on capital appreciation further supports a long-term horizon. A minimum holding period through key regulatory milestones in 2026/2027 is advised to assess the core investment thesis.
